Anticancer potential of magnolol for lung cancer treatment

BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities

(2010) Chih-Bo Hu et al.   CANCER SCIENCE

Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer

(2010) Andrew R. Reynolds   Dose-Response

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway

(2009) Ayesha B. Alvero et al.   CANCER

Small Cell Lung Cancer

(2009) Taimur Sher et al.   MAYO CLINIC PROCEEDINGS

High concentration of magnolol induces hepatotoxicity under serum-reduced conditions

(2009) Ying-Hsien Kao et al.   PHYTOMEDICINE